专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120093885A1 THERAPEUTIC VESICLES 审中-公开
标题翻译：治疗药物
公开(公告)号：US20120093885A1
公开(公告)日：2012-04-19
申请号：US13276142
申请日：2011-10-18
申请人： Susmita Sahoo , Douglas W. Losordo , David E. Zembower
发明人： Susmita Sahoo , Douglas W. Losordo , David E. Zembower
IPC分类号： A61K35/12 , A61P9/00 , A61P9/10 , A61P1/04 , A61P7/02 , A61P9/04 , A61P19/00 , A61P25/28 , A61P3/10 , A61P25/16 , A61P17/02 , A61P25/00 , A61P7/00 , C12N5/074 , A61K9/00
CPC分类号： A61K35/51 , A61K38/1774
摘要： The present technology provides compositions of vesicles, uses of vesicles, and methods relating to vesicles. For example, provided herein are vesicles derived from stem cells for use in regenerative therapies.
摘要翻译：本技术提供囊泡的组合物，囊泡的用途和与囊泡相关的方法。例如，本文提供的是来自用于再生治疗的干细胞的囊泡。

2. 发明申请

US20130101628A1 NOVEL VEGF MIMETIC PEPTIDE-BASED SCAFFOLDS FOR THERAPEUTIC ANGIOGENESIS AND METHODS FOR THEIR USE 审中-公开
标题翻译：用于治疗性血管生成的新型VEGF基于胶质细胞的药物及其使用方法
公开(公告)号：US20130101628A1
公开(公告)日：2013-04-25
申请号：US13459234
申请日：2012-04-29
申请人： Matthew J. Webber , Jörn Tongers , Douglas W. Losordo , Samuel I. Stupp
发明人： Matthew J. Webber , Jörn Tongers , Douglas W. Losordo , Samuel I. Stupp
IPC分类号： C07K14/00
CPC分类号： C07K14/001 , A61K38/18 , C07K14/52 , C07K2319/00
摘要： Disclosed herein is a completely synthetic cell-free therapy based on peptide amphiphile nanostructures designed to mimic the activity of vascular endothelial growth factor (VEGF), one of the most potent angiogenic signaling proteins. The VEGF-mimetic filaments disclosed herein were found to induce phosphorylation of VEGF receptors and induce pro-angiogenic behavior in endothelial cells, indicated by an enhancement in proliferation, survival and migration in vitro.
摘要翻译：本文公开了一种完全合成的无细胞疗法，其基于设计用于模拟血管内皮生长因子（VEGF）活性的肽两亲性纳米结构，血管内皮生长因子（VEGF）是最有效的血管生成信号蛋白之一。发现本文公开的VEGF-模拟细丝诱导VEGF受体的磷酸化并诱导内皮细胞中的促血管生成行为，由体外增殖，存活和迁移的增强指示。

3. 发明申请

US20100130414A1 Methods of Using E2F2 for the Treatment of Hypertension 有权
标题翻译：使用E2F2治疗高血压的方法
公开(公告)号：US20100130414A1
公开(公告)日：2010-05-27
申请号：US12447114
申请日：2007-10-29
申请人： Douglas W. Losordo , Gangjian Qin
发明人： Douglas W. Losordo , Gangjian Qin
IPC分类号： A61K38/18 , C12N15/74 , C12N5/10 , C07K14/00 , A61K31/7088 , A61P9/10
CPC分类号： C07K14/4705 , A61K38/00
摘要： The present invention features compositions and methods of treating or preventing hypertension or a cardiac indication. In particular embodiments, the invention provides E2F2 as a new therapeutic target for the treatment of hypertension or a cardiac indication, and methods of increasing the expression and/or activity of E2F2.
摘要翻译：本发明的特征在于治疗或预防高血压或心脏指征的组合物和方法。在具体实施方案中，本发明提供E2F2作为治疗高血压或心脏指征的新治疗靶标，以及增加E2F2的表达和/或活性的方法。

4. 发明申请

US20100135970A1 Methods for Reprogramming Adult Somatic Cells and Uses Thereof 审中-公开
标题翻译：重组人成体细胞及其用途的方法
公开(公告)号：US20100135970A1
公开(公告)日：2010-06-03
申请号：US12447091
申请日：2007-10-26
申请人： Raj Kishore , Douglas W. Losordo
发明人： Raj Kishore , Douglas W. Losordo
IPC分类号： A61K35/12 , C12N5/00 , C12N5/071 , C12N5/079 , A61P9/00
CPC分类号： A61K35/54 , C12N5/0662 , C12N2500/84 , C12N2501/155 , C12N2501/235 , C12N2501/33 , C12N2501/385 , C12N2501/39 , C12N2502/02 , C12N2506/00 , C12N2510/00
摘要： As described below, the present invention features methods for reprogramming somatic cells and related therapeutic compositions and methods.
摘要翻译：如下所述，本发明具有用于重编程体细胞的方法和相关的治疗组合物和方法。

5. 发明申请

US20090221683A1 Combination of CXCR4 Antagonist and Morphogen to Increase Angiogenesis 审中-公开
标题翻译：结合CXCR4拮抗剂和形态发生增加血管生成
公开(公告)号：US20090221683A1
公开(公告)日：2009-09-03
申请号：US12090046
申请日：2006-10-18
申请人： Douglas W. Losordo
发明人： Douglas W. Losordo
IPC分类号： A61K31/7088
CPC分类号： A61K38/193 , A61K31/7088 , A61K35/12 , A61K38/1825 , A61K38/1833 , A61K38/1858 , A61K45/06 , C12N5/0692 , A61K2300/00
摘要： The present invention generally provides methods for preventing, treating or reducing the severity of symptoms associated with tissue ischemia by administering a CXCR4 antagonist in combination with at least one nucleic acid encoding a morphogen or effective fragment thereof. In one embodiment, the methods include elevating peripheral blood endothelial progenitor cells (EPCs), bone marrow-derived stem cells (BMSCs), or both cell types. The invention has a wide spectrum of applications including reducing or eliminating tissue ischemia, especially tissue ischemia associated with a myocardial infarct (heart attack).
摘要翻译：本发明通常提供通过与编码形态发生体或其有效片段的至少一种核酸组合施用CXCR4拮抗剂来预防，治疗或降低与组织缺血相关的症状的严重性的方法。在一个实施方案中，所述方法包括升高外周血内皮祖细胞（EPCs），骨髓来源的干细胞（BMSCs）或两种细胞类型。本发明具有广泛的应用，包括减少或消除组织缺血，特别是与心肌梗死相关的组织缺血（心脏病发作）。

6. 发明申请

US20090155220A1 Use of Bone-Marrow Derived Stem Cells to Treat Ischemia 审中-公开
标题翻译：使用骨髓衍生干细胞治疗缺血
公开(公告)号：US20090155220A1
公开(公告)日：2009-06-18
申请号：US12090706
申请日：2006-10-20
申请人： Douglas W. Losordo
发明人： Douglas W. Losordo
IPC分类号： A61K35/12
CPC分类号： A61K35/28 , A61K2035/124 , C12N5/0663
摘要： Disclosed are cellular compositions and methods for preventing, treating or reducing the severity of tissue ischemia, particularly limb ischemia in a mammal. One inventive method includes administering a therapeutically effective amount of a cellular composition comprising a novel isolated multi-potent human bone marrow-derived stem cell (BMSC) having undetectable or negligible levels of markers of other known stem cells isolated from bone marrow. These cells can be expanded in vitro and formulated into cellular compositions and grafts capable of differentiating into components of functional new blood vessels when directly administered into ischemic limb tissue.
摘要翻译：公开了用于预防，治疗或降低组织缺血严重性，特别是哺乳动物肢体缺血的细胞组合物和方法。一种创造性方法包括施用治疗有效量的细胞组合物，其包含新型分离的多效人骨髓干细胞（BMSC），其具有从骨髓分离的其它已知干细胞标记物的不可检测或可忽略的水平。这些细胞可以在体外扩增并配制成细胞组合物和能够分化成功能性新血管成分的移植物，当直接施用于缺血性肢体组织时。

7. 发明授权

US09187540B2 Methods of using E2F2 for the treatment of hypertension 有权
标题翻译：使用E2F2治疗高血压的方法
公开(公告)号：US09187540B2
公开(公告)日：2015-11-17
申请号：US12447114
申请日：2007-10-29
申请人： Douglas W. Losordo , Gangjian Qin
发明人： Douglas W. Losordo , Gangjian Qin
IPC分类号： C07K14/47 , A61K38/00
CPC分类号： C07K14/4705 , A61K38/00
摘要： The present invention features compositions and methods of treating or preventing hypertension or a cardiac indication. In particular embodiments, the invention provides E2F2 as a new therapeutic target for the treatment of hypertension or a cardiac indication, and methods of increasing the expression and/or activity of E2F2.
摘要翻译：本发明的特征在于治疗或预防高血压或心脏指征的组合物和方法。在具体实施方案中，本发明提供E2F2作为治疗高血压或心脏指征的新治疗靶标，以及增加E2F2的表达和/或活性的方法。

8. 发明申请

US20120014879A1 USE OF TUMOR NECROSIS FACTOR-alpha RECEPTOR p75 FOR TREATMENT OF ISCHEMIA-INDUCED NEOVASCULARIZATION 审中-公开
标题翻译：肿瘤坏死因子-α受体p75用于治疗异位神经元诱导的新生血管的使用
公开(公告)号：US20120014879A1
公开(公告)日：2012-01-19
申请号：US12091405
申请日：2006-10-24
申请人： Douglas W. Losordo , David A. Goukassian
发明人： Douglas W. Losordo , David A. Goukassian
IPC分类号： A61K49/00 , C12N15/85 , A61K38/18 , A61K38/19 , A61P9/10 , A61K38/44 , C12N15/63 , C12N5/10 , G01N33/566 , C12Q1/68 , A61K48/00 , A61K38/30
CPC分类号： C12Q1/6858 , G01R31/025 , G01R31/3277 , C12Q2565/537 , C12Q2563/155 , C12Q2527/125
摘要： Improvements on the basic method used for BEAMing increase sensitivity and increase the signal-to-noise ratio. The improvements have permitted the determination of intrinsic error rates of various DNA polymerases and have permitted the detection of rare and subtle mutations in DNA isolated from plasma of cancer patients.
摘要翻译：用于BEAMing的基本方法的改进提高了灵敏度并提高了信噪比。这些改进允许确定各种DNA聚合酶的固有错误率，并允许检测从癌症患者血浆中分离的DNA中罕见且微妙的突变。

9. 发明申请

US20090105148A1 COMPOSITIONS AND METHODS FOR TREATING MYOCARDIAL INFARCTION 审中-公开
标题翻译：用于治疗心肌梗塞的组合物和方法
公开(公告)号：US20090105148A1
公开(公告)日：2009-04-23
申请号：US12294081
申请日：2007-03-23
申请人： Ryuichi Aikawa , Douglas W. Losordo
发明人： Ryuichi Aikawa , Douglas W. Losordo
IPC分类号： A61K48/00 , A61P9/00 , A61K38/18 , C12N5/10
CPC分类号： C07K14/61 , A01K67/027 , A61K48/005 , C12N2750/14143
摘要： The invention features compositions and methods that are useful for preventing or treating a cardiac disease or for promoting cardiac health following a myocardial infarction. The invention further features compositions and methods for promoting angiogenesis, cell proliferation, and/or decreasing apoptosis in muscle tissue, such as cardiac tissue. The invention provides for the expression of human growth hormone in cardiac muscle following a myocardial infarction.
摘要翻译：本发明的特征在于可用于预防或治疗心脏病或促进心肌梗塞后的心脏健康的组合物和方法。本发明还涉及用于促进血管生成，细胞增殖和/或降低肌肉组织如心脏组织中细胞凋亡的组合物和方法。本发明提供心肌梗塞后心肌中人生长激素的表达。

10. 发明授权

US09095580B2 Compositions and methods for regulating angiogenesis 有权
标题翻译：用于调节血管生成的组合物和方法
公开(公告)号：US09095580B2
公开(公告)日：2015-08-04
申请号：US13301475
申请日：2011-11-21
申请人： Takayuki Asahara , Douglas W. Losordo , Linda Isner
发明人： Jeffrey M. Isner , Takayuki Asahara , Douglas W. Losordo
IPC分类号： A61K35/28 , A61K35/44 , A61K45/06 , C12N5/071 , G01N33/569 , A61K35/12
CPC分类号： A61K35/44 , A61K45/06 , A61K2035/124 , C12N5/0692 , G01N33/56966
摘要： In accordance with the present invention, EC progenitors can be used in a method for regulating angiogenesis, i.e., enhancing or inhibiting blood vessel formation, in a selected patient and in some preferred embodiments for targeting specific locations. For example, the EC progenitors can be used to enhance angiogenesis or to deliver an angiogenesis modulator, e.g. anti- or pro-angiogenic agents, respectively to sites of pathologic or utilitarian angiogenesis. Additionally, in another embodiment, EC progenitors can be used to induce reendothelialization of an injured blood vessel, and thus reduce restenosis by indirectly inhibiting smooth muscle cell proliferation.
摘要翻译：根据本发明，EC祖细胞可以用于调节血管生成的方法中，即增强或抑制所选择的患者中的血管形成，以及针对特定位置的一些优选实施方案中。例如，EC祖细胞可用于增强血管发生或递送血管生成调节剂，例如血管生成调节剂。分别将抗血管生成剂或促血管生成剂分解为病理性或功能性血管发生部位。此外，在另一个实施方案中，EC祖细胞可用于诱导受损血管的内皮形成，并因此通过间接抑制平滑肌细胞增殖来减少再狭窄。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式